Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alloimmune refractoriness to platelet transfusions

S G Sandler1

  • 1Department of Medicine, Georgetown University Hospital, Washington, DC 20007-2197, USA.

Current Opinion in Hematology
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rh immune globulin: an interfering substance in compatibility testing.

Immunohematology·2019
Same author

DEL phenotype.

Immunohematology·2017
Same author

Bloody Brilliant: A History of Blood Groups and Blood Groupers.

Immunohematology·2017
Same author

Immunosuppressive protocols for transplantation and certain hematologic malignancies can prevent the primary immune response to the D blood group antigen.

Immunohematology·2013
Same author

Education in transfusion medicine for medical students and doctors.

Vox sanguinis·2013
Same author

Laboratory methods for Rh immunoprophylaxis: a review.

Immunohematology·2011
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Platelet refractoriness, a common issue in patients receiving frequent transfusions, occurs when alloantibodies reduce treatment effectiveness. Strategies focus on preventing human leukocyte antigen (HLA) alloimmunization and exploring novel platelet substitutes.

Area of Science:

  • Transfusion Medicine
  • Immunology
  • Hematology

Background:

  • Repeated transfusions can lead to alloimmunization, causing platelet refractoriness.
  • Platelet refractoriness is defined by poor post-transfusion platelet count increments.
  • Human leukocyte antigen (HLA) antibodies are a primary cause of this refractoriness.

Purpose of the Study:

  • To review the phenomenon of platelet refractoriness.
  • To discuss current and investigational strategies for preventing and managing HLA alloimmunization.
  • To explore alternative transfusion products and modified platelets.

Main Methods:

  • Literature review of platelet transfusion refractoriness.
  • Analysis of prevention strategies for HLA alloimmunization.

Related Experiment Videos

  • Overview of novel therapeutic approaches and platelet substitutes.

    • Main Results:

    • HLA-matched or cross-matched platelets can improve outcomes in alloimmunized patients.
    • Prevention strategies include reducing transfusion frequency, filtration, and ultraviolet B irradiation.
    • Investigational approaches involve modifying platelet immunogenicity and exploring substitutes.

    Conclusions:

    • Preventing HLA alloimmunization is crucial for managing platelet refractoriness.
    • A range of strategies, from established methods to novel therapies, are being explored.
    • Optimizing platelet transfusion efficacy remains a key challenge in transfusion medicine.